A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma
Learning Objectives After completing this course, the reader will be able to: Discuss clinical trial data for treatment with bortezomib monotherapy and bortezomib-based combination therapy in patients with multiple myeloma who have received at least one prior therapy.Discuss the management of the most common adverse events associated with bortezomib, including peripheral neuropathy and thrombocytopenia.Describe prognostic factors in patients with multiple myeloma who have received at least one prior therapy. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.The... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2006 |
Schlagwörter: | Netherlands / Cancer Research / Oncology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26811503 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://www.openaccessrepository.it/record/114623 |
Learning Objectives After completing this course, the reader will be able to: Discuss clinical trial data for treatment with bortezomib monotherapy and bortezomib-based combination therapy in patients with multiple myeloma who have received at least one prior therapy.Discuss the management of the most common adverse events associated with bortezomib, including peripheral neuropathy and thrombocytopenia.Describe prognostic factors in patients with multiple myeloma who have received at least one prior therapy. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com